君实生物(01877.HK)注射用无菌粉末JS213获药物临床试验批准

阿斯达克财经
06 Feb

君实生物(01877.HK) 公布,收到国家药品监督管理局通知,AWT020注射用无菌粉末(项目代号︰JS213)的临床试验申请获得批准,同意本品开展单药以及联合其他抗肿瘤治疗在晚期恶性肿瘤患者中的临床试验。JS213是PD-1和白细胞介素-2双功能性抗体融合蛋白,主要用于晚期恶性肿瘤的治疗。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-02-05 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10